Cargando…
An Innovative Option for Venous Reconstruction After Pancreaticoduodenectomy: the Left Renal Vein
INTRODUCTION: Pancreatic ductal adenocarcinoma has a high mortality rate with limited treatment options. One option is pancreaticoduodenectomy, although complete resection may require venous resection. Pancreaticoduodenectomy with venous resection and reconstruction is becoming a more common practic...
Autores principales: | , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Springer-Verlag
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1852389/ https://www.ncbi.nlm.nih.gov/pubmed/17436125 http://dx.doi.org/10.1007/s11605-007-0131-1 |
_version_ | 1782133044963966976 |
---|---|
author | Smoot, Rory L. Christein, John D. Farnell, Michael B. |
author_facet | Smoot, Rory L. Christein, John D. Farnell, Michael B. |
author_sort | Smoot, Rory L. |
collection | PubMed |
description | INTRODUCTION: Pancreatic ductal adenocarcinoma has a high mortality rate with limited treatment options. One option is pancreaticoduodenectomy, although complete resection may require venous resection. Pancreaticoduodenectomy with venous resection and reconstruction is becoming a more common practice with many choices for venous reconstruction. We describe the technique of using the left renal vein as a conduit for venous reconstruction during pancreaticoduodenectomy. METHODS: The technique for use of the left renal vein as an interposition graft for venous reconstruction during pancreaticoduodenectomy is described as well as outcomes for nine patients that have undergone the procedure. RESULTS: Nine patients, seven men, with a mean age of 57 years, have undergone the operation. There were eight interposition grafts and one patch graft. Mean operating time was 7.8 hours, and mean tumor size was 3.4 cm. Eight patients had node-positive disease, and six had involvement of the vein. Mean hospital stay was 14 days and perioperative morbidity included a superficial wound infection, delayed gastric emptying, ascites, and gastrointestinal bleeding in one patient each. Creatinine ranged from 0.8–1.1 mg/dl preoperatively and from 0.7–1.3 mg/dl at discharge. Mean follow-up was 6.8 months with normal creatinine values noted through the follow-up period. Two patients had died during follow-up from recurrent disease at 8.3 and 18.2 months after the operation. CONCLUSIONS: The left renal vein provides an additional choice for an autologous graft during pancreaticoduodenectomy with venous resection. The ease of harvesting the graft and maintenance of renal function distinguish its use. |
format | Text |
id | pubmed-1852389 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2007 |
publisher | Springer-Verlag |
record_format | MEDLINE/PubMed |
spelling | pubmed-18523892007-04-17 An Innovative Option for Venous Reconstruction After Pancreaticoduodenectomy: the Left Renal Vein Smoot, Rory L. Christein, John D. Farnell, Michael B. J Gastrointest Surg Article INTRODUCTION: Pancreatic ductal adenocarcinoma has a high mortality rate with limited treatment options. One option is pancreaticoduodenectomy, although complete resection may require venous resection. Pancreaticoduodenectomy with venous resection and reconstruction is becoming a more common practice with many choices for venous reconstruction. We describe the technique of using the left renal vein as a conduit for venous reconstruction during pancreaticoduodenectomy. METHODS: The technique for use of the left renal vein as an interposition graft for venous reconstruction during pancreaticoduodenectomy is described as well as outcomes for nine patients that have undergone the procedure. RESULTS: Nine patients, seven men, with a mean age of 57 years, have undergone the operation. There were eight interposition grafts and one patch graft. Mean operating time was 7.8 hours, and mean tumor size was 3.4 cm. Eight patients had node-positive disease, and six had involvement of the vein. Mean hospital stay was 14 days and perioperative morbidity included a superficial wound infection, delayed gastric emptying, ascites, and gastrointestinal bleeding in one patient each. Creatinine ranged from 0.8–1.1 mg/dl preoperatively and from 0.7–1.3 mg/dl at discharge. Mean follow-up was 6.8 months with normal creatinine values noted through the follow-up period. Two patients had died during follow-up from recurrent disease at 8.3 and 18.2 months after the operation. CONCLUSIONS: The left renal vein provides an additional choice for an autologous graft during pancreaticoduodenectomy with venous resection. The ease of harvesting the graft and maintenance of renal function distinguish its use. Springer-Verlag 2007-03-03 2007-04 /pmc/articles/PMC1852389/ /pubmed/17436125 http://dx.doi.org/10.1007/s11605-007-0131-1 Text en © The Society for Surgery of the Alimentary Tract 2007 |
spellingShingle | Article Smoot, Rory L. Christein, John D. Farnell, Michael B. An Innovative Option for Venous Reconstruction After Pancreaticoduodenectomy: the Left Renal Vein |
title | An Innovative Option for Venous Reconstruction After Pancreaticoduodenectomy: the Left Renal Vein |
title_full | An Innovative Option for Venous Reconstruction After Pancreaticoduodenectomy: the Left Renal Vein |
title_fullStr | An Innovative Option for Venous Reconstruction After Pancreaticoduodenectomy: the Left Renal Vein |
title_full_unstemmed | An Innovative Option for Venous Reconstruction After Pancreaticoduodenectomy: the Left Renal Vein |
title_short | An Innovative Option for Venous Reconstruction After Pancreaticoduodenectomy: the Left Renal Vein |
title_sort | innovative option for venous reconstruction after pancreaticoduodenectomy: the left renal vein |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1852389/ https://www.ncbi.nlm.nih.gov/pubmed/17436125 http://dx.doi.org/10.1007/s11605-007-0131-1 |
work_keys_str_mv | AT smootroryl aninnovativeoptionforvenousreconstructionafterpancreaticoduodenectomytheleftrenalvein AT christeinjohnd aninnovativeoptionforvenousreconstructionafterpancreaticoduodenectomytheleftrenalvein AT farnellmichaelb aninnovativeoptionforvenousreconstructionafterpancreaticoduodenectomytheleftrenalvein AT smootroryl innovativeoptionforvenousreconstructionafterpancreaticoduodenectomytheleftrenalvein AT christeinjohnd innovativeoptionforvenousreconstructionafterpancreaticoduodenectomytheleftrenalvein AT farnellmichaelb innovativeoptionforvenousreconstructionafterpancreaticoduodenectomytheleftrenalvein |